Table 1 Characteristics at baseline in adolescents with JIA (n = 15) receiving IACs to the TMJs (n = 22)
Baseline characteristic | Value |
|---|---|
Female, no. (%) | 12 (80) |
Age at injections, yrs | 15 (11, 16) |
Age at JIA onset, yrs. | 11 (8, 14) |
Disease duration, yrs. | 1 (0, 5) |
JIA-category, no (%) | |
 Oligoarthritis persistent | 6 (40) |
 Polyarthritis RF negative | 5 (33) |
 Oligoarthritis extended | 3 (20) |
 Enthesitis related arthritis | 1 (7) |
Disease activity, no (%)a | |
 Active | 15 (100) |
 Remission on medication | – |
 Remission off medication | – |
Medication baseline, no (%) | |
 No DMARDs | 6 (40) |
 DMARDs (MTX) | 3 (20) |
 Biologics combination | 6 (40) |
Disease activity variables | |
 JADAS10 baseline (n = 8) | 15.8 (12.9, 49.1) |
 No.of active joints (n = 14) | 2.0 (1.0, 3.0) |
 PRpainVAS (n = 10) | 4.8 (3.3, 7.6) |
 PRgloVAS (n = 10) | 5.5 (3.3, 7.1) |
 MDgloVAS (n = 12) | 2.5 (1.6, 4.5) |
 ESR (mm/h) (n = 12) | 6.5 (3.5, 10.5) |
 TMJ-examination to injection, days | 14.0 (1.0, 68.0) |
 Follow-up, months | 22.0 (16.0, 23.0) |
 Injection to 2-months follow-up, (n = 14) | 2.0 (1.8, 3.3) |
 Injection to 1-year follow-up, months (n = 15) | 12.0 (11.0, 13.0) |
 Injection to 2-year follow-up, months (n = 11) | 22.0 (22.0, 23.0) |
 Triamcinolone hexacetonide, dose, mg (n = 14) | 20.0 (9.5, 20.0) |
 Methylprednisolone acetate, dose, mg (n = 1) | 40.0 (n = 1) |
 Push-pull technique / No. TMJs (%) | 10/22 (46) |
 Needle length, mm/ No. TMJs | 25 mm/15, 30 mm/7 |